SNPX News and Press, Synaptogenix Inc. From 06/07/21

Synaptogenix (SNPX), an ultramicrocap with a market cap of just $24.4M, is down 5.6% following the approval of Biogen's (BIIB) Aduhelm (aducanumab).Shares earlier in the day were up by more than 10%.The company's lead compound, bryostatin, is in phase 2 for moderately severe to seve...

Synaptogenix Responds to FDA Approval of Aducanumab PR Newswire NEW YORK , June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a st...

Synaptogenix Announces Approval for Nasdaq Stock Market Listing PR Newswire NEW YORK , June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, ann...

Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market PR Newswire NEW YORK , May 19, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, an...

Detroit, Michigan--(Newsfile Corp. - May 10, 2021) - Synaptogenix, Inc (OTCQB: SNPX) will be presenting at the Benzinga Global Small Cap Conference taking place on May 13-14, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global ...

Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum PR Newswire NEW YORK , April 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company focused on developing...

Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update PR Newswire NEW YORK , April 1, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, toda...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire NEW YORK , March 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerati...

Synaptogenix to Present at Upcoming Scientific Industry Conferences PR Newswire NEW YORK , Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases...